Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-01-12 |
Cempra (USA - NC) |
$93.7 million |
private placement |
|
Infectious diseases |
Private placement |
2016-01-12 |
Epizyme (USA - MA) |
$ 130.1 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-01-12 |
Valera, a Moderna Therapeutics' venture (USA - MA) |
up to $20 million |
grant |
Bill & Melinda Gates Foundation |
Infectious diseases |
Grant |
2016-01-12 |
Tmunity (USA - PA) |
$10 million |
financing round |
Penn Medicine (USA - PA) Lilly Asia Ventures (China) |
Cancer - Oncology - Autoimmune diseases - Infectious diseases |
Financing round |
2016-01-11 |
AB2 Bio (Switzerland) |
CHF 21 million ($ 21 million - € 19.3 million) |
series B financing round |
undisclosed new and existing investors |
Inflammatory diseases |
Series B financing round |
2016-01-11 |
Reneuron (UK) |
£2.1 million |
grant |
Innovate UK (UK) |
Regenerative Medicine |
Grant |
2016-01-11 |
Novimmune (Switzerland) |
CHF 30 million ($29.8 million - €27.6 million) |
financing round |
|
Cancer - Oncology - Rare diseases - Immunological diseases |
Financing round |
2016-01-08 |
Zymeworks (Canada) |
$61.5 Million |
series A financing round |
BDC Capital (Canada) Celgene (USA - NJ) CTI Life Sciences Fund (Canada) Eli Lilly (USA - IN) Fonds de solidarité FTQ (Canada) Lumira Capital (Canada) Perceptive Advisors (USA - NY) Teralys Capital (Canada) Northleaf Venture Catalyst Fund (Canada) Brace Pharma Capital (USA - MD) Merlin Nexus (USA - NY) |
Cancer - Oncology |
Series A financing round |
2016-01-07 |
C4 Therapeutics (USA - MA) |
$73 million |
series A financing round |
Cobro Ventures (USA) Cormorant Asset Management (USA - MA) The Kraft Group (USA - MA) EG Capital Group (USA - NY) Roche (Switzerland) Novartis (Switzerland) angel investors |
|
Series A financing round |
2016-01-07 |
Galena Biopharma (USA - OR) |
$21.75 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-01-06 |
Neovacs (France) |
€ 5 million |
grant |
Bpifrance (France) |
Autoimmune diseases - Dermatological diseases |
Grant |
2015-12-29 |
Oryzon Genomics (Spain) |
$ 1.3 million (€ 1.18 million) |
loan |
Ministry of Economy and Competitiveness of the Spanish Government (Spain) |
Cancer - Oncology - Neurodegenerative diseases |
Loan |
2015-12-22 |
Merrimack Pharmaceuticals (USA - MA) |
$175 million |
private placement |
|
|
Private placement |
2015-12-17 |
Poietis (France) |
€2.5 million |
series A financing round, grant, loan |
WiSEED (France) business angels BPIfrance (France) Conseil Régional d’Aquitaine (France) Banque Populaire Aquitaine Centre Atlantique (France) EADS Développement (France) Michelin Développement (France) |
Technology - Services |
Series A financing round |
2015-12-15 |
GamaMabs Pharma (France) |
€15 million |
series B financing round |
Edmond de Rothschild Investment Partners (EdRIP) (France) InnoBio (France) Irdinov (France) Alto Invest (France) iXO Private Equity) (France) |
Cancer - Oncology |
Series B financing round |
2015-12-15 |
Oryzon Genomics (Spain) |
|
IPO |
|
Cancer - Oncology - Neurodegenerative diseases |
IPO |
2015-12-14 |
Seventure Partners (France) |
€ 160 million |
fundraising |
Danone (France) MultiCap Croissance (France) Natixis (France) Novartis (Switzerland) Tereos (France) Tournier (France) Unigrains (France) Bel (France) Lesaffre (France) |
|
Fundraising |
2015-12-11 |
Kite Pharma (USA - CA) |
$287.6 million |
private placement |
|
Cancer - Oncology - Rare diseases |
Private placement |
2015-12-10 |
Freeline Therapeutics (UK) |
£25 million |
series A financing round |
Syncona (UK) |
Hematologic diseases - Genetic diseases - Rare diseases |
Series A financing round |
2015-12-10 |
TETRA consortium lead by Videregen (UK) |
€ 6.8 million |
grant |
European Commission’s Horizon 2020 programme |
|
Grant |